Key facts
- Notable investors include CNT Tech, DB Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for InnoAul
- ·The full record, as it builds
Funding rounds
No funding rounds for InnoAul are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InnoAul
Operator of an AI biomedical company intended to deliver precision diagnostics for atopic dermatitis and other chronic skin diseases using RNA transcriptome analysis and minimally invasive technologies. The company offers a diagnostic value chain that combines microneedle-based minimally invasive patches, RNA transcriptome analysis and AI-driven patient classification, enabling customers to achieve accurate, patient-friendly diagnostics, predict treatment responses and develop personalized therapeutic strategies.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Ownership
- Privately Held (backing)
InnoAul doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InnoAul shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InnoAul in its N-PORT filings yet. We sweep new filings monthly.